NextCure, launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/06/16 | $67,000,000 |
Canaan Partners Lilly Asia Ventures OrbiMed Advisors Pfizer Strategic Investments Group Sofinnova Ventures | undisclosed | |
| 11/13/18 | $93,000,000 | Series B |
ArrowMark Partners Bay City Capital Canaan Partners Hillhouse Capital Management  Lilly Asia Ventures NS Investment OrbiMed Advisors Pfizer Venture Investments Ping An Ventures Quan Capital Surveyor Capital Taiho Ventures | undisclosed |
